+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Advanced Therapy Medicinal Products Market Size, Share & Trends Analysis Report by Therapy Type (Cell Therapy, Gene Therapy, Tissue Engineered Product), Region (North America, Europe, APAC, ROW), and Segment Forecasts, 2023-2030

  • PDF Icon

    Report

  • 120 Pages
  • December 2023
  • Region: Global
  • Grand View Research
  • ID: 5415538
The global advanced therapy medicinal products market size is expected to reach USD 90.98 billion by 2030, registering a CAGR of 16.8% during the forecast period. The ATMPs (Advanced Therapy Medicinal Products) exhibit the potential to cure diseases by addressing their root cause rather than symptomatic treatment. Thus, ATMPs help deliver transformative advantages which are not offered by conventional treatments. These factors are expected to drive the market over the forecast period.

The breakthrough approvals of Tecartus and Abecma post-approval of Zolgensma, Kymriah, and Yescarta have bolstered the exceptional advancements in this space. These approvals have spurred the investment flow in this arena thereby driving revenue growth. Key companies are adopting various operation models to accelerate the product manufacturing process.

Furthermore, the market witnessed several acquisitions by players that intended to enter or expand their existing business in this field. Acquisitions of Kite Pharma by Gilead Life Science, AveXis by Novartis, and Juno Therapeutics by Celgene are some major & recent examples. These acquisitions depict the increasing interest of well-established pharma companies in this market. Increasing competition for gene therapy buyouts can lead to hefty premiums.

On the other hand, with the growing consumer demands, the ATMP manufacturers are outsourcing their product manufacturing thereby creating lucrative opportunities for the contract manufacturing organizations. Thus, several CDMOs have expanded their facilities. For instance, in January 2021, FUJIFILM Diosynth Biotechnologies invested USD 40 million for the establishment of a new process development and manufacturing facility for advanced therapies and viral vectors.

Advanced Therapy Medicinal Products Market Report Highlights

  • The geographical expansion of Yescarta and Kymriah in Japan and Europe has encouraged the investors to support the development in this space
  • Recent approvals of gene therapies have significantly accelerated the clinical trials in this segment
  • COVID-19 pandemic has opened new areas for key players to invest in T-cell research for viral infections
  • The research community is actively evaluating the potential of advanced therapies in COVID-19 patients, thereby aiding in market growth
  • North America accounted for the largest revenue share in 2022 owing to the exponential rise in clinical trials pertaining to advanced therapies
  • Strong pipeline of ATMPs in the U.S. accelerated revenue generation in the region
  • Also, the shifting focus of U.S.-based companies from conventional drug development to ATMPS is driving regional growth
  • In Asia-Pacific, the market is expected to witness the fastest CAGR owing to expanding ATMP landscape in emerging markets such as China at the forefront
  • Expanding business of China-based CDMOs has driven regional market growth
  • Key companies are undertaking various strategic initiatives to maintain their market position. Collaboration between ViGeneron GmbH and Biogen Inc. in January 2021 is one of the notable examples of collaboration in this space
  • The companies collaborated on the development of an AAV-based gene therapy product for the treatment of inherited eye diseases.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Therapy Type
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. Internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1
1.9.2. Objective 2
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Therapy type outlook
2.2.2. Regional outlook
2.3. Competitive Insights
Chapter 3. Advanced Therapy Medicinal Products Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Advanced Therapy Medicinal Products Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Advanced Therapy Medicinal Products: Type Estimates & Trend Analysis
4.1. Advanced Therapy Medicinal Products Market: Key Takeaways
4.2. Advanced Therapy Medicinal Products Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Cell Therapy
4.3.1. Cell therapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Gene Therapy
4.4.1. Gene therapy market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. Tissue Engineered Product
4.5.1. Tissue engineered product market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Advanced Therapy Medicinal Product Market: Regional Estimates & Trend Analysis
5.1. Regional Outlook
5.2. Advanced Therapy Medicinal Products Market by Region: Key Marketplace Takeaway
5.3. North America
5.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.3.2. U.S.
5.3.2.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.3.3. Canada
5.3.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.4. Europe
5.4.1. UK
5.4.1.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.4.2. Germany
5.4.2.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.4.3. France
5.4.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.4.4. Italy
5.4.4.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.4.5. Spain
5.4.5.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.4.6. Sweden
5.4.6.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.4.7. Norway
5.4.7.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.4.8. Denmark
5.4.8.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.5. Asia-Pacific
5.5.1. Japan
5.5.1.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.5.2. China
5.5.2.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.5.3. India
5.5.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.5.4. Australia
5.5.4.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.5.5. Thailand
5.5.5.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.5.6. South Korea
5.5.6.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.6. Latin America
5.6.1. Brazil
5.6.1.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.6.2. Mexico
5.6.2.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.6.3. Argentina
5.6.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.7. MEA
5.7.1. Saudi Arabia
5.7.1.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.7.2. South Africa
5.7.2.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.7.3. UAE
5.7.3.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
5.7.4. Kuwait
5.7.4.1. Market estimates and forecasts, 2018-2030 (Revenue, USD Million)
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Company/Competition Categorization
6.2.1. Spark Therapeutics, Inc.
6.2.1.1. Company overview
6.2.1.2. Financial performance
6.2.1.3. Product benchmarking
6.2.1.4. Strategic initiatives
6.2.2. Bluebird Bio, Inc
6.2.2.1. Company overview
6.2.2.2. Financial performance
6.2.2.3. Product benchmarking
6.2.2.4. Strategic initiatives
6.2.3. Novartis AG
6.2.3.1. Company overview
6.2.3.2. Financial performance
6.2.3.3. Product benchmarking
6.2.3.4. Strategic initiatives
6.2.4. UniQure N.V.
6.2.4.1. Company overview
6.2.4.2. Financial performance
6.2.4.3. Product benchmarking
6.2.4.4. Strategic initiatives
6.2.5. Celgene Corporation
6.2.5.1. Company overview
6.2.5.2. Financial performance
6.2.5.3. Product benchmarking
6.2.5.4. Strategic initiatives
6.2.6. Gilead Lifesciences, Inc
6.2.6.1. Company overview
6.2.6.2. Financial performance
6.2.6.3. Product benchmarking
6.2.6.4. Strategic initiatives
6.2.7. Kolon TissueGene, Inc
6.2.7.1. Company overview
6.2.7.2. Financial performance
6.2.7.3. Product benchmarking
6.2.7.4. Strategic initiatives
6.2.8. JCR Pharmaceuticals Co., Ltd.
6.2.8.1. Company overview
6.2.8.2. Financial performance
6.2.8.3. Product benchmarking
6.2.8.4. Strategic initiatives
6.2.9. MEDIPOST
6.2.9.1. Company overview
6.2.9.2. Financial performance
6.2.9.3. Product benchmarking
6.2.9.4. Strategic initiatives
6.2.10. Vericel Corporation
6.2.10.1. Company overview
6.2.10.2. Financial performance
6.2.10.3. Product benchmarking
6.2.10.4. Strategic initiatives
6.2.11. PHARMICELL Co., Ltd
6.2.11.1. Company overview
6.2.11.2. Financial performance
6.2.11.3. Product benchmarking
6.2.11.4. Strategic initiatives
6.2.12. Organogenesis Inc.
6.2.12.1. Company overview
6.2.12.2. Financial performance
6.2.12.3. Product benchmarking
6.2.12.4. Strategic initiatives
List of Tables
Table 1 List of Abbreviation
Table 2 North America advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 3 North America advanced therapy medicinal products market, by region, 2018-2030 (USD Million)
Table 4 U.S. advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 5 Canada advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 6 Europe advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 7 Europe advanced therapy medicinal products market, by region, 2018-2030 (USD Million)
Table 8 Germany advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 9 UK advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 10 France advanced therapy medicinal products, by therapy type, 2018-2030 (USD Million)
Table 11 Italy advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 12 Spain advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 13 Sweden advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 14 Norway advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 15 Denmark advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 16 Asia-Pacific advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 17 Asia-Pacific advanced therapy medicinal products market, by region, 2018-2030 (USD Million)
Table 18 China advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 19 Japan advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 20 India advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 21 Thailand advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 22 South Korea advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 23 Latin America advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 24 Latin America advanced therapy medicinal products market, by region, 2018-2030 (USD Million)
Table 25 Brazil advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 26 Mexico advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 27 Argentina advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 28 Middle East and Africa advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 29 Middle East and Africa advanced therapy medicinal products market, by region, 2018-2030 (USD Million)
Table 30 South Africa advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 31 Saudi Arabia advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 32 UAE advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
Table 33 Kuwait advanced therapy medicinal products market, by therapy type, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Market research approaches
Figure 5 Value-chain-based sizing & forecasting
Figure 6 QFD modeling for market share assessment
Figure 7 Market formulation & validation
Figure 8 Advanced therapy medicinal products: market outlook
Figure 9 Parent market outlook
Figure 10 Related/ancillary market outlook
Figure 11 Penetration and growth prospect mapping
Figure 12 Industry value chain analysis
Figure 13 Advanced therapy medicinal products market driver impact
Figure 14 Advanced therapy medicinal products market restraint impact
Figure 15 Advanced therapy medicinal products market strategic initiatives analysis
Figure 16 Advanced therapy medicinal products market: type movement analysis
Figure 17 Advanced therapy medicinal products market: type outlook and key takeaways
Figure 18 Cell therapy market estimates and forecasts, 2018-2030 (USD Million)
Figure 19 Gene therapy market estimates and forecasts, 2018-2030 (USD Million)
Figure 20 Tissue engineered product market estimates and forecasts, 2018-2030 (USD Million)
Figure 21 Global Advanced therapy medicinal products market: regional movement analysis
Figure 22 Global Advanced therapy medicinal products market: regional outlook and key takeaways
Figure 23 North America market estimates and forecasts, 2018-2030 (USD Million)
Figure 24 U.S. market estimates and forecasts, 2018-2030 (USD Million)
Figure 25 Canada market estimates and forecasts, 2018-2030 (USD Million)
Figure 26 Europe market estimates and forecasts, 2018-2030 (USD Million)
Figure 27 UK market estimates and forecasts, 2018-2030 (USD Million)
Figure 28 Germany market estimates and forecasts, 2018-2030 (USD Million)
Figure 29 France market estimates and forecasts, 2018-2030 (USD Million)
Figure 30 Italy market estimates and forecasts, 2018-2030 (USD Million)
Figure 31 Spain market estimates and forecasts, 2018-2030 (USD Million)
Figure 32 Sweden market estimates and forecasts, 2018-2030 (USD Million)
Figure 33 Norway market estimates and forecasts, 2018-2030 (USD Million)
Figure 34 Denmark market estimates and forecasts, 2018-2030 (USD Million)
Figure 35 Asia-Pacific market estimates and forecasts, 2018-2030 (USD Million)
Figure 36 Japan market estimates and forecasts, 2018-2030 (USD Million)
Figure 37 China market estimates and forecasts, 2018-2030 (USD Million)
Figure 38 India market estimates and forecasts, 2018-2030 (USD Million)
Figure 39 Australia market estimates and forecasts, 2018-2030 (USD Million)
Figure 40 Thailand market estimates and forecasts, 2018-2030 (USD Million)
Figure 41 South Korea market estimates and forecasts, 2018-2030 (USD Million)
Figure 42 Latin America market estimates and forecasts, 2018-2030 (USD Million)
Figure 43 Brazil market estimates and forecasts, 2018-2030 (USD Million)
Figure 44 Mexico market estimates and forecasts, 2018-2030 (USD Million)
Figure 45 Argentina market estimates and forecasts, 2018-2030 (USD Million)
Figure 46 Middle East and Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 47 Saudi Arabia market estimates and forecasts, 2018-2030 (USD Million)
Figure 48 South Africa market estimates and forecasts, 2018-2030 (USD Million)
Figure 49 UAE market estimates and forecasts, 2018-2030 (USD Million)
Figure 50 Kuwait market estimates and forecasts, 2018-2030 (USD Million)

Companies Mentioned

  • Spark Therapeutics, Inc.
  • Bluebird Bio, Inc
  • Novartis AG
  • UniQure N.V.
  • Celgene Corporation
  • Gilead Lifesciences, Inc
  • Kolon TissueGene, Inc
  • JCR Pharmaceuticals Co., Ltd.
  • MEDIPOST
  • Vericel Corporation
  • PHARMICELL Co., Ltd
  • Organogenesis Inc.

Methodology

Loading
LOADING...

Table Information